Avandia - Revision history

David Leloup: added link to BMJ study

2010-07-23T15:46:53Z

added link to BMJ study

Marisa de Andrade at 14:03, 21 March 2010

2010-03-21T14:03:12Z

Claire Robinson: /* Links to heart attack risks */

2010-03-04T14:20:42Z

Links to heart attack risks

Marisa de Andrade at 20:14, 2 March 2010

2010-03-02T20:14:41Z

Claire Robinson at 12:05, 24 February 2010

2010-02-24T12:05:16Z

Marisa de Andrade: /* Links to heart attack risks */

2010-02-23T23:20:56Z

Links to heart attack risks

Marisa de Andrade: /* Links to heart attack risks */

2010-02-23T23:20:17Z

Links to heart attack risks

Marisa de Andrade: /* Background */

2010-02-23T23:18:43Z

Background

Marisa de Andrade: Avandia Controversy moved to Avandia

2009-05-01T21:49:01Z

Avandia Controversy moved to Avandia

David at 21:01, 1 May 2009

2009-05-01T21:01:06Z

@@ Line 3: / Line 3: @@
 ==Background==
-[[Avandia]] or Rosiglitazone, is one of [[GlaxoSmithKline]]'s blockbuster drugs for type 2 diabetes. It was raking in 4.6 million pounds a day in the early months of 2007, when an independent researcher who worked at the Cleveland Clinic in America, [[Steven Nissen]], published a controversial meta-analysis of the drug in the [[New England Journal of Medicine]] ([[NEJM]]).  Nissen added up heart problem data in all the previously published studies of Avandia in order to examine the drug’s safety profile. He concluded that users are 43 per cent more likely to have heart attacks and that there is an even higher increase in the risk of fatal heart problems.<ref>Nissen, S., and Wolski, K. (2007) Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. ''The New England Journal of Medicine'', volume 356:2457-2471.</ref>
+[[Avandia]] or Rosiglitazone, is one of [[GlaxoSmithKline]]'s blockbuster drugs for type 2 diabetes. It was raking in 4.6 million pounds a day in the early months of 2007, when an independent researcher who worked at the Cleveland Clinic in America, [[Steven Nissen]], published a controversial meta-analysis of the drug in the [[New England Journal of Medicine]] ([[NEJM]]).  Nissen added up heart problem data in all the previously published studies of Avandia in order to examine the drug’s safety profile. He concluded that users are 43 per cent more likely to have heart attacks and that there is an even higher increase in the risk of fatal heart problems.<ref>Nissen, S., and Wolski, K. (2007) [http://content.nejm.org/cgi/content/full/NEJMoa072761 Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes]. ''The New England Journal of Medicine'', volume 356:2457-2471.</ref>
 In April 2008, The Scotsman reported on NHS Scotland's reaction to Nissen's meta-analysis.<ref>LYNDSAY MOSS and MARISA DE ANDRADE, [http://news.scotsman.com/latestnews/Doctors-demand-freeze-on-use.3953015.jp Doctors Demand Freeze on use of diabetes drug for heart patients], The Scotsman, 7 April 2008, accessed 24 Feb 2010</ref>

@@ Line 17: / Line 17: @@
 :'Nissen said the recording showed that the executives hoped to persuade him not to publish his study by suggesting that they had contradictory information they would share with him in a joint study. “In retrospect, it seems clear that neither statement was true,” Dr. Nissen said. “They did not have contradictory data, and they never intended to cooperate in any analyses.”'<ref>Harris, G. ''The New York Times.'' 22 February 2010. [http://www.nytimes.com/2010/02/23/health/23niss.html?pagewanted=1 A Face-Off on the Safety of a Drug for Diabetes] Accessed 2 March 2010.</ref>
 ==Notes==
 <references/>

@@ Line 9: / Line 9: @@
 ==Links to heart attack risks==
-After a two year inquiry, the US Senate Finance Committee issued a report in February 2010 stating '''Avandia''''s manufacturer, [[GlaxoSmithKline]], knew of possible heart attack risks tied to its drug and 'tried to play down findings that the drug could increase cardiovascular risks while also working to minimize findings that a rival medication might reduce such risks'. <ref>The Washington Post (Associated Press). 21 February 2010. [http://www.washingtonpost.com/wp-dyn/content/article/2010/02/20/AR2010022003547.html Senate report ties GlaxoSmithKline diabetes drug Avandia to heart attack risks] Accessed 23 February 2010.</ref> The senate asked the [[FDA]] to explain 'why it allowed a clinical trial of Avandia to continue even after the agency estimated that the drug caused 83,000 heart attacks between 1999 and 2007'.<ref>The Washington Post (Associated Press). 21 February 2010. [http://www.washingtonpost.com/wp-dyn/content/article/2010/02/20/AR2010022003547.html Senate report ties GlaxoSmithKline diabetes drug Avandia to heart attack risks] Accessed 23 February 2010.</ref> Two FDA officials Food and Drug Administration are recommending the drug is pulled from the market.<ref>Harris, G. ''The New York Times'' [http://www.nytimes.com/2010/02/20/health/policy/20avandia.html  Research Ties Diabetes Drug to Heart Woes] Accessed 23 February 2010.</ref>
+After a two year inquiry, the US Senate Finance Committee issued a report in February 2010 stating '''Avandia''''s manufacturer, [[GlaxoSmithKline]], knew of possible heart attack risks tied to its drug and 'tried to play down findings that the drug could increase cardiovascular risks while also working to minimize findings that a rival medication might reduce such risks'. <ref>The Washington Post (Associated Press). 21 February 2010. [http://www.washingtonpost.com/wp-dyn/content/article/2010/02/20/AR2010022003547.html Senate report ties GlaxoSmithKline diabetes drug Avandia to heart attack risks] Accessed 23 February 2010.</ref> The senate asked the [[FDA]] to explain 'why it allowed a clinical trial of Avandia to continue even after the agency estimated that the drug caused 83,000 heart attacks between 1999 and 2007'.<ref>The Washington Post (Associated Press). 21 February 2010. [http://www.washingtonpost.com/wp-dyn/content/article/2010/02/20/AR2010022003547.html Senate report ties GlaxoSmithKline diabetes drug Avandia to heart attack risks] Accessed 23 February 2010.</ref> Two Food and Drug Administration (FDA) officials are recommending the drug is pulled from the market.<ref>Harris, G. ''The New York Times'' [http://www.nytimes.com/2010/02/20/health/policy/20avandia.html  Research Ties Diabetes Drug to Heart Woes] Accessed 23 February 2010.</ref>
 ==Secret Tapes==

@@ Line 10: / Line 10: @@
 After a two year inquiry, the US Senate Finance Committee issued a report in February 2010 stating '''Avandia''''s manufacturer, [[GlaxoSmithKline]], knew of possible heart attack risks tied to its drug and 'tried to play down findings that the drug could increase cardiovascular risks while also working to minimize findings that a rival medication might reduce such risks'. <ref>The Washington Post (Associated Press). 21 February 2010. [http://www.washingtonpost.com/wp-dyn/content/article/2010/02/20/AR2010022003547.html Senate report ties GlaxoSmithKline diabetes drug Avandia to heart attack risks] Accessed 23 February 2010.</ref> The senate asked the [[FDA]] to explain 'why it allowed a clinical trial of Avandia to continue even after the agency estimated that the drug caused 83,000 heart attacks between 1999 and 2007'.<ref>The Washington Post (Associated Press). 21 February 2010. [http://www.washingtonpost.com/wp-dyn/content/article/2010/02/20/AR2010022003547.html Senate report ties GlaxoSmithKline diabetes drug Avandia to heart attack risks] Accessed 23 February 2010.</ref> Two FDA officials Food and Drug Administration are recommending the drug is pulled from the market.<ref>Harris, G. ''The New York Times'' [http://www.nytimes.com/2010/02/20/health/policy/20avandia.html  Research Ties Diabetes Drug to Heart Woes] Accessed 23 February 2010.</ref>
 ==Notes==
 <references/>

@@ Line 5: / Line 5: @@
 [[Avandia]] or Rosiglitazone, is one of [[GlaxoSmithKline]]'s blockbuster drugs for type 2 diabetes. It was raking in 4.6 million pounds a day in the early months of 2007, when an independent researcher who worked at the Cleveland Clinic in America, [[Steven Nissen]], published a controversial meta-analysis of the drug in the [[New England Journal of Medicine]] ([[NEJM]]).  Nissen added up heart problem data in all the previously published studies of Avandia in order to examine the drug’s safety profile. He concluded that users are 43 per cent more likely to have heart attacks and that there is an even higher increase in the risk of fatal heart problems.<ref>Nissen, S., and Wolski, K. (2007) Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. ''The New England Journal of Medicine'', volume 356:2457-2471.</ref>
-In April 2008, The Scotsman reported on NHS Scotland's reaction to Nissen's meta-analysis: [http://news.scotsman.com/latestnews/Doctors-demand-freeze-on-use.3953015.jp Doctors Demand Freeze on use of diabetes drug for heart patients ]
+In April 2008, The Scotsman reported on NHS Scotland's reaction to Nissen's meta-analysis.<ref>LYNDSAY MOSS and MARISA DE ANDRADE, [http://news.scotsman.com/latestnews/Doctors-demand-freeze-on-use.3953015.jp Doctors Demand Freeze on use of diabetes drug for heart patients], The Scotsman, 7 April 2008, accessed 24 Feb 2010</ref>
 ==Links to heart attack risks==

← Older revision	Revision as of 21:49, 1 May 2009
(No difference)

← Older revision		Revision as of 21:01, 1 May 2009
Line 1:		Line 1:
−	{{Template:~~Pharma_Badge~~}}	+	{{Template:Pharma_Portal_badge}}

	==Background==		==Background==